Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11β-HSD1 inhibitor classes are under investigation by the pharmaceutical industry to treat type 2 diabetes and obesity.
Keywords: 11β-hydroxysteroid dehydrogenase, glucocorticoid receptor, cortisol, ex vivo activity, insulin resistance, Cushing's syndrome
Rights & PermissionsPrintExport